Cadrenal Therapeutics announced the acquisition of eXIthera Pharmaceuticals' complete portfolio of investigational Factor XIa inhibitors, significantly expanding its anticoagulation pipeline to address underserved segments of the $38 billion global anticoagulation market. The acquisition includes both intravenous and oral Factor XIa inhibitors designed for acute and chronic anticoagulation settings.
Strategic Pipeline Enhancement
The acquisition brings two lead assets to Cadrenal's portfolio: frunexian, a first-in-class Phase 2-ready intravenous Factor XIa inhibitor, and EP-7327, an IND-ready oral small molecule candidate. Frunexian is specifically designed for acute care settings where contact activation of coagulation by medical devices plays a significant role, including cardiopulmonary bypass, catheter thrombosis, and other blood-contacting implanted cardiac devices.
"With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants," said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. "These newly acquired assets will expand Cadrenal's capabilities in an effort to address even more critical gaps in current antithrombotic treatment, especially for patients for whom current therapies are unreliable or carry excessive bleeding risk."
Differentiated Mechanism of Action
Unlike current anticoagulants that increase bleeding risk by broadly impairing coagulation, eXIthera's compounds are mechanism-based inhibitors of Factor XIa, offering high potency, selectivity, and tunable pharmacokinetics. Factor XIa inhibition represents one of the most active areas of current thrombosis research, potentially offering safer anticoagulation profiles.
The acquisition also includes an extensive portfolio of additional novel Factor XIa small molecules, providing Cadrenal with a comprehensive platform for developing next-generation anticoagulants across multiple therapeutic applications.
Deal Structure and Financial Terms
Under the acquisition agreement, eXIthera will receive milestone payments totaling up to $15 million, contingent upon achieving specific clinical and regulatory milestones. Additionally, eXIthera will receive royalties on global sales of the acquired assets upon future commercialization. The deal structure enables Cadrenal to focus capital deployment on advancing clinical development of both tecarfarin and the newly acquired assets.
A pre-existing license agreement allows Sichuan Haisco Pharmaceuticals to retain rights to frunexian in China, where the company has completed a successful Phase 1 trial. Under this arrangement, Cadrenal will receive royalties on future Chinese sales of frunexian.
Comprehensive Anticoagulation Strategy
The acquisition reinforces Cadrenal's vision of becoming a category leader in anticoagulation therapy. The company's lead investigational product, tecarfarin, is a novel oral vitamin K antagonist designed to address unmet needs in anticoagulation therapy, particularly where direct-acting oral anticoagulants remain inadequate or unproven.
Tecarfarin has received Orphan Drug Designation and fast-track designation for preventing systemic thromboembolism in patients with end-stage kidney disease and atrial fibrillation. The company also received Orphan Drug Designation for preventing thromboembolism in patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices.
"With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk," added Pham.
